Table 1 Characteristics of the patients.
All patients enrolled (n = 101) | Transplanted patients (n = 87) | Relapsed patients (n = 40) | Refractory patients (n = 47) | Non transplanted patients (n = 14) | |
---|---|---|---|---|---|
Age (years), median (range) | 54 (19–69) | 52 (19–69) | 46 (19–67) | 54 (23–69) | 62.5 (20–68) |
Sex | |||||
Female | 45 (44.6) | 40 (46) | 20 (50) | 20 (42.6) | 5 (35.7) |
Male | 56 (55.4) | 47 (54) | 20 (50) | 27 (57.4) | 9 (64.3) |
Previous auto HSCT | 9 (8.9) | 8 (9.2) | 5 (12.5) | 3 (6.4) | 1 (7.1) |
Diagnosis | |||||
Acute myeloid leukemia | 93 (92.1) | 82 (94.0) | 36 (90.0) | 46 (97.9) | 11 (78.6) |
de novo | 79 (84.9) | 69 (84.1) | 34 (94.4) | 35 (76.1) | 10 (90.9) |
Secondary | 13 (14.0) | 12 (14.6) | 2 (5.6) | 10 (21.7) | 1 (9.1) |
Therapy-related | 1 (1.1) | 1 (1.2) | 0 | 1 (2.2) | 0 |
Acute Lymphoblastic Leukemia | 8 (7.9) | 5 (5.7) | 4 (10.0) | 1 (2.1) | 3 (21.4) |
de novo | 7 (87.5) | 4 (80.0) | 3 (75) | 1 (100) | 3 (100) |
Secondary | 1 (12.5) | 1 (20.0) | 1 (25) | 0 | 0 (0) |
B-lineage | 7 (87.5) | 4 (80.0) | 3 (75) | 1 (100) | 3 (100) |
T- lineage | 1 (12.5) | 1 (20.0) | 1 (25) | 0 | 0 (0) |
Ph pos | 2 (25.0) | 1 (20.0) | 1 (50) | 0 | 1 (33.3) |
Cytogenetics | |||||
Low riska | 3 (3) | 3 (3.4) | 2 (5) | 1 (2.1) | 0 |
Intermediate riska | 49 (48.5) | 43 (49.4) | 23 (57.5) | 20 (42.6) | 6 (42.9) |
High riska | 36 (35.6) | 29 (33.3) | 10 (25) | 19 (40.4) | 7 (50) |
Unknown | 13 (12.9) | 12 (13.8) | 5 (12.5) | 7 (14.9) | 1 (7.1) |
Molecular biology | |||||
BCR-ABL mutated | 2/96 (2.1) | 1/82 (1.2) | 1/37 (2.6) | 0/44 | 1/14 (7.1) |
AF4-MLL mutated | 1/6 (16.7) | 0/3 | 0/2 | 0/1 | 1/3 (33.3) |
AML1 ETO mutated | 2/91 (2.2) | 2/80 (2.5) | 1/36 (2.8) | 1/44 (2.3) | 0/11 |
FLT3-ITD mutated | 21/91 (23.1) | 19/80 (23.8) | 12/36 (33.3) | 7/44 (15.9) | 2/11 (18.2) |
CEBPA mutated | 1/90 (1.1) | 1/79 (1.3) | 1/36 (2.8) | 0/43 | 0/11 |
NPM1 mutated | 24/90 (26.7) | 21/79 (26.6) | 15/36 (41.7) | 6/43 (14) | 3/11 (27.3) |
MLL-PTD mutated | 1/90 (1.1) | 1/79 (1.3) | 1/36 (2.8) | 0/43 | 0/11 |
Sorror score | |||||
0 | 39 (38.6) | 33 (37.9) | 13 (32.5) | 20 (42.6) | 6 (42.9) |
1 | 43 (42.6) | 39 (44.8) | 19 (47.5) | 20 (42.6) | 4 (28.6) |
2 | 11 (10.9) | 10 (11.5) | 5 (12.5) | 5 (10.6) | 1 (7.1) |
3 | 7 (6.9) | 5 (5.7) | 3 (7.5) | 2 (4.3) | 2 (14.3) |
>3 | 1 (1.0) | 0 (0) | 0 (0) | 0 (0) | 1 (7.1) |
Blasts PB % at enrollement | 30 (0–100) | 28.5 (0–100) | 40 (0–95) | 21 (0–100) | 70 (4–100) |
Platelets ×109/L at enrollement | 34 (3–471) | 36 (3–471) | 35 (3–327) | 43 (6–471) | 22 (10–165) |
Ferritin ng/mL at enrollement | 1757 (25–7745) | 1740 (122–6853) | 1836 (122–6853) | 1700 (460–5565) | 1914 (25–7745) |
Albumin, g/L at enrollement | 42 (12–63) | 42 (12–63) | 43 (12–60.2) | 41 (27–63) | 40 (30–44.5) |
Donor typeb | |||||
URD | 48 (55.2) | 48 (55.2) | 25 (62.5) | 23 (48.9) | – |
10/10 matched | 26 (54.2) | 26 (54.2) | 11 (44.0) | 15 (65.2) | – |
mis-matched | 17 (35.4) | 17 (35.4) | 12 (48.0) | 5 (21.7) | – |
CB | 6 (6.9) | 6 (6.9) | 11 (27.5) | 2 (4.3) | – |
Haploidentical | 33 (37.9) | 33 (37.9) | 4 (10.0) | 22 (46.8) | – |
Female donor for male recipientb | 18 (20.7) | 18 (20.7) | 6 (15.0) | 12 (25.5) | – |
HSC sourceb | |||||
PBSC | 44 (50.6) | 44 (50.6) | 25 (62.5) | 19 (40.4) | – |
BM | 37 (42.5) | 37 (42.5) | 11 (27.5) | 26 (55.3) | – |
CB | 6 (6.9) | 6 (6.9) | 4 (10.0) | 2 (4.3) | – |
CMV serostatusb | |||||
R CMV+/D CMV+ | 42 (51.2) | 42 (51.2) | 19 (48.7) | 23 (53.5) | – |
R CMV+/D CMV− | 30 (36.6) | 30 (36.6) | 15 (38.5) | 15 (34.9) | – |
R CMV-/D CMV+ | 6 (7.3) | 6 (7.3) | 3 (7.7) | 3 (7) | – |
R CMV−/D CMV− | 4 (4.9) | 4 (4.9) | 2 (5.1) | 2 (4.7) | – |
Conditioning regimenb | |||||
TBF-full | 82 (94.3) | 82 (94.3) | 37 (92.5) | 45 (95.7) | – |
TBF- reduced intensity | 4 (4.6) | 4 (4.6) | 2 (5.0) | 2 (4.3) | – |
Other | 1 (1.1) | 1 (1.1) | 1 (2.5) | 0 | – |